Novel, Intra-articular Wnt Pathway Inhibitor May Improve Knee Osteoarthritis

Yusuf Yazici, MD
Yusuf Yazici, MD
Yusuf Yazici, MD, discusses results from a trial evaluating a small molecule inhibitor of the Wnt pathway for the treatment of knee osteoarthritis.

The following video is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 .

CHICAGO – Yusuf Yazici, MD, discusses results from a phase 2, randomized trial evaluating a novel small molecule Wnt pathway inhibitor for the treatment of knee osteoarthritis (OA), presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, in Chicago, Illinois. 

SM04690 is being investigated as a potential disease-modifying drug for knee OA.  

Reference

Yazici Y, McAlindon TE, Gibofsky A, et al. Results from a 52 Week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, Wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis. Presented at: ACR/ARHP 2018 Annual Meeting; October 19-24, 2018; Chicago, IL. Abstract 935.

Disclosure: Dr Yazici is chief medical officer at Samumed.

This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.